| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf7925a5cca66f1625e1fa44f5b5b400 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-10 |
| filingDate |
2013-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40e20ad207f5e0679653d65995ef326f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58a2a5d2464cbde28b907645025e4c87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31ccdbe0282e53b2e2f48e0cf1126f05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e3e3a5a74031f4a401456e5b08f1807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dae5758d9afdf8c6abe18cc648c8136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_314f9c86c3137db15829d796d3bada4f |
| publicationDate |
2015-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9102670-B2 |
| titleOfInvention |
Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors |
| abstract |
There is provided a compound of formula I: n nor a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023107592-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020005063-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016067258-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9717736-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10034884-B2 |
| priorityDate |
2006-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |